The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder

成纤维细胞生长因子受体 癌症研究 成纤维细胞生长因子受体1 酪氨酸激酶 医学 成纤维细胞生长因子 受体酪氨酸激酶 化学 受体 内分泌学 生物 内科学 生物化学
作者
Robert Jr. Roskoski
出处
期刊:Pharmacological Research [Elsevier BV]
卷期号:151: 104567-104567 被引量:146
标识
DOI:10.1016/j.phrs.2019.104567
摘要

The human fibroblast growth factor family consists of 22 factors and five transmembrane receptors. Of the 22 factors, eighteen are secreted while four of them function exclusively within the cell. Four of the fibroblast growth factor receptors (FGFRs) possess intracellular protein-tyrosine kinase activity while the fifth (FGFRL1) has a short 105-residue intracellular non-enzymatic component. The FGFR protein kinase domain consists of a bi-lobed structure that is similar to that of all other protein kinases. FGFR gene alterations occur in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach. The majority (66 %) of FGFR gene alterations involve gene amplifications, followed by mutations (26 %), and rearrangements that produce fusion proteins (8 %). Erdafitinib was the first orally effective FGFR antagonist approved by the FDA (2019) for the treatment of advanced cancer, that of the urinary bladder. FGF23 suppresses phosphate reabsorption in the proximal tubules of the kidney; FGF23 blockade allows phosphate reabsorption to occur and leads to elevated serum phosphate levels. Erdafitinib and several other, but not all, FGFR antagonists produce hyperphosphatemia. Erdafitinib binds to an inactive DGF-Din conformation of FGFR1 and is classified as a type I½ inhibitor. Similarly, dovitinib, AZD4547, CH5183284, infigratinib, lenvatinib, LY2874455, and lucitanib are type I½ inhibitors. The inactive conformations contain an autoinhibitory brake that is made up of three main residues: an asparagine (N) within the αC-β4 back loop, a glutamate (E) corresponding to the second hinge residue, and a lysine (K) in the β8-strand (the NEK triad). PDGFRα/β, Kit, CSF1R, VEGFR1/2/3, Flt3, Tek, and Tie protein kinases are also regulated by a similar autoinhibitory brake mechanism. Ponatinib binds to FGFR4 in a DFG-Dout conformation and is classified as a type II inhibitor. Futibatinib, roblitinib, H3B-6527, fisogatinib, and PRN1371 bind covalently to their FGFR target and are classified as type VI inhibitors. Nintedanib, pazopanib, pemigatinib, rogaratinib, fisogatinib, and PRN1371 are FGFR inhibitors lacking drug-enzyme crystal structures. All of the aforementioned FGFR antagonists are orally effective. The development of FGFR inhibitors has lagged behind those of other receptor protein-tyrosine kinases. However, the FDA approval of erdafitinib for the treatment of urinary bladder cancers may stimulate additional work targeting the many other FGFR-driven neoplasms.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wxf完成签到,获得积分10
1秒前
大个的应助被开心德地采纳,获得10
1秒前
xu完成签到,获得积分10
1秒前
wq完成签到,获得积分10
1秒前
2秒前
3秒前
欢喜的非笑完成签到 ,获得积分10
3秒前
李子青发布了新的文献求助10
3秒前
3秒前
光光发布了新的文献求助10
3秒前
4秒前
CipherSage的应助被你好采纳,获得10
4秒前
4秒前
730发布了新的文献求助10
5秒前
wanci的应助被青柠味薯片采纳,获得10
5秒前
5秒前
duanzou完成签到,获得积分10
6秒前
Orange的应助被明亮飞双采纳,获得10
6秒前
7秒前
科研通AI6.4的应助被奈者CO采纳,获得100
7秒前
我是老大的应助被weihua采纳,获得30
7秒前
ding的应助被开心德地采纳,获得20
8秒前
8秒前
LuckyYu发布了新的文献求助10
9秒前
bademing完成签到,获得积分10
10秒前
long发布了新的文献求助10
10秒前
DrLee完成签到,获得积分10
10秒前
余香的应助被小卢采纳,获得10
10秒前
duanzou发布了新的文献求助10
10秒前
11秒前
完美世界的应助被金鱼采纳,获得10
11秒前
13秒前
13秒前
13秒前
小L完成签到,获得积分10
13秒前
13秒前
bbh56完成签到,获得积分10
14秒前
完美世界的应助被吱吱采纳,获得10
14秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986